DrugPatentWatch Database Preview
Drugs in Development Information for INC280
Try a free trial
See Plans and Pricing
Summary for INC280
| US Patents | 17 |
| International Patents | 256 |
| US Patent Applications | 51 |
| WIPO Patent Applications | 37 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2017-05-31) |
| Vendors | 62 |
US Patents for INC280
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| INC280 | ➤ Sign Up | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | ➤ Sign Up |
| INC280 | ➤ Sign Up | Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide | Novartis AG (Basel, CH) | ➤ Sign Up |
| INC280 | ➤ Sign Up | Combination therapy | NOVARTIS AG (Basel, CH) | ➤ Sign Up |
| INC280 | ➤ Sign Up | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,- 4]triazin-2-yl]benzamide and processes related to preparing the same | INCYTE INCORPORATION (Wilmington, DE) INCYTE HOLDINGS CORPORATION (Wilmington, DE) | ➤ Sign Up |
| INC280 | ➤ Sign Up | Imidazotriazines and imidazopyrimidines as kinase inhibitors | Incyte Corporation (Wilmington, DE) | ➤ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for INC280
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| INC280 | European Patent Office | 3131552 | 2034-04-16 | ➤ Sign Up |
| INC280 | Japan | 2017514806 | 2034-04-16 | ➤ Sign Up |
| INC280 | Japan | 2019070012 | 2034-04-16 | ➤ Sign Up |
| INC280 | New Zealand | 629860 | 2034-04-16 | ➤ Sign Up |
| INC280 | World Intellectual Property Organization (WIPO) | 2015160868 | 2034-04-16 | ➤ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
